Skip to main content
SpringerLink
Log in

Noninvasive Tracer Techniques to Characterize Angiogenesis

  • Chapter
Molecular Imaging II

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 185/2))

Abstract

Great efforts are being made to develop antiangiogenesis drugs for treatment of cancer as well as other diseases. Some of the compounds are already in clinical trials. Imaging techniques allowing noninvasive monitoring of corresponding molecular processes can provide helpful information for planning and controlling corresponding therapeutic approaches but will also be of interest for basic science. Current nuclear medicine techniques focus on the development of tracer targeting the vascular endothelial growth factor (VEGF) system, matrix metalloproteinases (MMP), the ED-B domain of a fibronectin isoform, and the integrin αvβ3. In this chapter, the recent tracer developments as well as the preclinical and the clinical evaluations are summarized and the potential of the different approaches to characterize angiogenesis are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB (2003) Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 46:2376–2396

    Article  PubMed  Google Scholar 

  • Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E (2001) Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40:2373–2378

    Article  PubMed  Google Scholar 

  • Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M (2005) Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-Galacto-RGD in cancer patients. J Nucl Med 46:1333–1341

    PubMed  Google Scholar 

  • Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res 12:3942–3949

    Article  PubMed  Google Scholar 

  • Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM (2005) Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11:7053s–7063s

    Article  PubMed  Google Scholar 

  • Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, Gimple LW, Powers ER, Mousa SA, Sarembock IJ (2001) Selective αvβ3-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 103:1906–1911

    PubMed  Google Scholar 

  • Blankenberg FG, Mandl S, Cao YA, O’Connell-Rodwell C, Contag C, Mari C, Gaynutdinov TI, Vanderheyden JL, Backer MV, Backer JM (2004) Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med 45:1373–1380

    PubMed  Google Scholar 

  • Blankenberg FG, Backer MV, Levashova Z, Patel V, Backer JM (2006) In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 33: 841–848

    Article  PubMed  Google Scholar 

  • Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102: 75–85

    Article  PubMed  Google Scholar 

  • Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164

    Article  PubMed  Google Scholar 

  • Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815–1822

    Article  PubMed  Google Scholar 

  • Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257

    Article  PubMed  Google Scholar 

  • Castellani P, Dorcaratto A, Pau A, Nicola M, Siri A, Gasparetto B, Zardi L, Viale G (2000) The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningiomas. Acta Neurochir 142:277–282

    Article  Google Scholar 

  • Chavakis E, Riecke B, Lin J, Linn T, Bretzel RG, Preissner KT, Brownlee M, Hammes HP (2002) Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia 45:262–267

    Article  PubMed  Google Scholar 

  • Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS (2004a) Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med 45:1776–1783

    PubMed  Google Scholar 

  • Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, Conti PS (2004b) MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6:350–359

    Article  PubMed  Google Scholar 

  • Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Bading JR, Laug WE, Conti PS (2004c) MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 31:1081–1089

    Article  PubMed  Google Scholar 

  • xChen X, Park R, Shahinian AH, Bading JR, Conti PS (2004d) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31:11–19

    Article  Google Scholar 

  • Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS (2004e) MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15:41–49

    Article  PubMed  Google Scholar 

  • Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS (2004f) Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3: 96–104

    Article  PubMed  Google Scholar 

  • Chen X, Park R, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Moats RA, Bading JR, Laug WE, Conti PS (2005) Longitudinal MicroPET Imaging of Brain Tumor Growth with F-18-labeled RGD peptide. Mol Imaging Biol 29:1–7

    Google Scholar 

  • Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL (2002) The development of [124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62:5912–5919

    PubMed  Google Scholar 

  • Cornelissen B, Oltenfreiter R, Kersemans V, Staelens L, Frankenne F, Foidart JM, Slegers G (2005) In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 32:431–436

    Article  PubMed  Google Scholar 

  • Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236

    Article  PubMed  Google Scholar 

  • Cross MJ, Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201–207

    Article  PubMed  Google Scholar 

  • Curran S, Murray GI (2000) Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36:1621–1630

    Article  PubMed  Google Scholar 

  • Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I, Rodrigo T, Haubner R (2006) [99mTc]HYNIC-RGD for imaging integrin αvβ3 expression. Nucl Med Biol 33:945–952

    Article  PubMed  Google Scholar 

  • Decristoforo C, Santos I, Pietzsch HJ, Duatti A, Smith CJ, Rey A, Alberto R, von Guggenberg E, Haubner R (2007) Comparision of in vitro and in vivo properties of 99mTc-cRGD peptides labelled using different novel Tc-cores. Q J Nucl Med Mol Imaging 51:33–41

    PubMed  Google Scholar 

  • Demartis S, Tarli L, Borsi L, Zardi L, Neri D (2001) Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 28:534–539

    Article  PubMed  Google Scholar 

  • Eliceiri BP, Cheresh DA (2000) Role of αv integrins during angiogenesis. Cancer J Sci Am 6:S245–S249

    Google Scholar 

  • Ellis LM, Liu W, Fan F, Jung YD, Reinmuth N, Stoeltzing O, Takeda A, Akagi M, Parikh AA, Ahmad S (2002) Synopsis of angiogenesis inhibitors in oncology. Oncology 16:14–22

    PubMed  Google Scholar 

  • Fei X, Zheng QH, Hutchins GD, Liu X, Stone KL, Carlson KA, Mock BH, Winkle WL, Glick-Wilson BE, Miller KD, Fife RS, Sledge GW, Sun HB, Carr RE (2002) Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents. J Label Compd Radiopharm 45:449–470

    Article  Google Scholar 

  • Fei X, Zheng Q-H, Liu X, Wang J-Q, Stone KL, Miller KD, Sledge GW, Hutchins GD (2003a) Synthesis of MMP inhibitor radiotracer [11C]CGS 25966, a new potential PET tumor imaging agent. J Label Compd Radiopharm 46:343–351

    Article  Google Scholar 

  • Fei X, Zheng QH, Liu X, Wang JQ, Sun HB, Mock BH, Stone KL, Miller KD, Sledge GW, Hutchins GD (2003b) Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorg Med Chem Lett 13:2217–2222

    Article  PubMed  Google Scholar 

  • Foda HD, Zucker S (2001) Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 6:478–482

    Article  PubMed  Google Scholar 

  • Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18

    PubMed  Google Scholar 

  • Furumoto S, Iwata R, Ido T (2002) Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitors for cancer imaging. J Label Compd Radiopharm 45:975–986

    Article  Google Scholar 

  • Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2:562–577

    Article  PubMed  Google Scholar 

  • Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111–122

    PubMed  Google Scholar 

  • Hagedorn M, Bikfalvi A (2000) Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 34:89–110

    Article  PubMed  Google Scholar 

  • Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 2:529–533

    Article  PubMed  Google Scholar 

  • Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214–221

    Article  PubMed  Google Scholar 

  • Harris JM, Martin NE, Modi M (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539–551

    Article  PubMed  Google Scholar 

  • Haubner R (2006) αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 13:54–63

    Article  Google Scholar 

  • Haubner R, Wester HJ (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 10:1439–1455

    Article  PubMed  Google Scholar 

  • Haubner R, Finsinger D, Kessler H (1997) Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer Therapy. Angew Chem Int Ed Engl 36:1374–1389

    Article  Google Scholar 

  • Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stocklin G, Schwaiger M (1999) Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40:1061–1071

    PubMed  Google Scholar 

  • Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M (2001a) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42:326–336

    PubMed  Google Scholar 

  • Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M (2001b) Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781–1785

    PubMed  Google Scholar 

  • Haubner R, Kuhnast B, Wester HJ, Weber WA, Huber R, Senekowitsch-Schmidtke R, Ziegler SI, Goodman SL, Kessler H, Schwaiger M (2002) [F-18]-RGD-Peptides Conjugated with Hydrophilic Tetrapeptides for the Noninvasive Determination of the αvβ3 Integrin. J Nucl Med 43 (Suppl):89P

    Google Scholar 

  • Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ (2004a) Synthesis and biological evaluation of a 99mTc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin 43:26–32

    PubMed  Google Scholar 

  • Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M (2004b) [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15:61–69

    Article  PubMed  Google Scholar 

  • Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M (2005) Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2:29

    Article  Google Scholar 

  • Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178–93

    Article  PubMed  Google Scholar 

  • Hynes R (1985) Molecular biology of fibronectin. Annu Rev Cell Biol 1:67–90

    Article  PubMed  Google Scholar 

  • Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918–921

    Article  PubMed  Google Scholar 

  • Hynes RO, Bader BL, Hodivala-Dilke K (1999) Integrins in vascular development. Braz J Med Biol Res 32:501–510

    Article  PubMed  Google Scholar 

  • Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y (1996) Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87:602–611

    PubMed  Google Scholar 

  • Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC (2002a) Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res 62:6146–6151

    PubMed  Google Scholar 

  • Janssen MLH, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf I, Edwards DS, Rajopadhye WJ, Corstens FHM, Boerman OC (2002b) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor imaging. Cancer Biother Radiopharm 17:641–646

    Article  PubMed  Google Scholar 

  • Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M (1999) Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J Med Chem 42:1723–1738

    Article  PubMed  Google Scholar 

  • Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774

    Article  PubMed  Google Scholar 

  • Kuhnast B, Bodenstein C, Wester HJ, Weber WA (2003) Carbon-11 labeling of a N-sulfonylamino acid derivative: a potential tracer for MMP-2 and MMP-9 imaging. J Label Compd Radiopharm 46:1093–1103

    Article  Google Scholar 

  • Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M, Weber WA (2004) Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol 31:337–344

    Article  PubMed  Google Scholar 

  • Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, Ono M (2001) Angiogenesis factors. Intern Med 40:565–572

    Article  PubMed  Google Scholar 

  • Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galardy RE (1998) Matrix metalloproteinase inhibitors: a structure-activity study. J Med Chem 41:199–223

    Article  PubMed  Google Scholar 

  • Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, Kapiotis S, Hamwi A, Weich HA, Valent P, Angelberger P, Dudczak R, Virgolini I (2001) Characterization of 123I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 91:789–796

    Article  PubMed  Google Scholar 

  • Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A, Pirich C, Angelberger P, Dudczak R (2003) Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 14:1274–1277

    Article  PubMed  Google Scholar 

  • Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, Traub-Weidinger T, Graf S, Beheshti M, Schmid M, Angelberger P, Dudczak R (2004) Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q J Nucl Med Mol Imaging 48:198–206

    PubMed  Google Scholar 

  • Matter A (2001) Tumor angiogenesis as a therapeutic target. Drug Discov Today 6:1005–1024

    Article  PubMed  Google Scholar 

  • Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15:1271–1275

    Article  PubMed  Google Scholar 

  • Neufeld G, Cohen T, Gitay-Goren H, Poltorak Z, Tessler S, Sharon R, Gengrinovitch S, Levi BZ (1996) Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 15:153–158

    Article  PubMed  Google Scholar 

  • Nguyen M, Arkell J, Jackson CJ (2001) Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 33:960–970

    Article  PubMed  Google Scholar 

  • Oltenfreiter R, Staelens L, Lejeune A, Dumont F, Frankenne F, Foidart JM, Slegers G (2004) New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nucl Med Biol 31:459–468

    Article  PubMed  Google Scholar 

  • Oltenfreiter R, Staelens L, Hillaert U, Heremans A, Noel A, Frankenne F, Slegers G (2005a) Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents. Appl Radiat Isot 62:903–913

    Article  PubMed  Google Scholar 

  • Oltenfreiter R, Staelens L, Labied S, Kersemans V, Frankenne F, Noel A, Van de Wiele C, Slegers G (2005b) Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Cancer Biother Radiopharm 20:639–647

    Article  PubMed  Google Scholar 

  • Pelmenschikov V, Siegbahn PE (2002) Catalytic mechanism of matrix metalloproteinases: two-layered ONIOM study. Inorg Chem 41:5659–5666

    Article  PubMed  Google Scholar 

  • Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, Kessler H, Schwaiger M, Wester HJ (2004a) Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med 45:892–902

    PubMed  Google Scholar 

  • Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, Henriksen G, Kessler H, Schwaiger M, Wester HJ (2004b) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta 92:317–327

    Article  Google Scholar 

  • Rosen L (2000) Antiangiogenic strategies and agents in clinical trials. Oncologist 1:20–27

    Article  Google Scholar 

  • Rundhaug JE (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9:267–285

    Article  PubMed  Google Scholar 

  • Ruoslahti E, Pierschbacher MD (1987) New perspectives in cell adhesion: RGD and integrins. Science 238:491–497

    Article  PubMed  Google Scholar 

  • Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9: 571–579

    PubMed  Google Scholar 

  • Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA (1999) Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J Clin Invest 103:47–54

    Article  PubMed  Google Scholar 

  • Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ (2002) In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of αvβ3 integrin for tumor imaging. Bioconjug Chem 13:561–570

    Article  PubMed  Google Scholar 

  • Su ZF, He J, Rusckowski M, Hnatowich DJ (2003) In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Nucl Med Biol 30:141–149

    Article  PubMed  Google Scholar 

  • Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood 94:192–198

    PubMed  Google Scholar 

  • Thumshirn G, Hersel U, Goodman SL, Kessler H (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 9:2717–2725

    Article  PubMed  Google Scholar 

  • Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA (2006) Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47: 1127–1135

    PubMed  Google Scholar 

  • van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, Krenning EP, de Jong M (2000) Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 90:186–198

    Article  PubMed  Google Scholar 

  • Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166

    Article  PubMed  Google Scholar 

  • Wang W, McMurray JS, Wu Q, Campbell ML, Li C (2005) Convenient solid-phase synthesis of diethylenetriaminepenta-acetic acid (DTPA)- conjugated cyclic RGD peptide analogues. Cancer Biother Radiopharm 20:547–556

    Article  PubMed  Google Scholar 

  • Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, Gambhir SS, Chen X (2005) microPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 46:1707–1718

    PubMed  Google Scholar 

  • Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, Chen X (2006) Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2. J Nucl Med 47:113–121

    PubMed  Google Scholar 

  • Zheng QH, Fei X, Liu X, Wang JQ, Bin Sun H, Mock BH, Lee Stone K, Martinez TD, Miller KD, Sledge GW, Hutchins GD (2002) Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 29:761–770

    Article  PubMed  Google Scholar 

  • Zheng QH, Fei X, DeGrado TR, Wang JQ, Lee Stone K, Martinez TD, Gay DJ, Baity WL, Mock BH, Glick-Wilson BE, Sullivan ML, Miller KD, Sledge GW, Hutchins GD (2003) Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [(11)C]methyl ester. Nucl Med Biol 30:753–760

    Article  PubMed  Google Scholar 

  • Zheng QH, Fei X, Liu X, Wang JQ, Stone KL, Martinez TD, Gay DJ, Baity WL, Miller KD, Sledge GW, Hutchins GD (2004) Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4′-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4′-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbut anamide. Nucl Med Biol 31:77–85

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Nuklearmedizin, Medizinische Universität Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria

    Roland Haubner

Authors
  1. Roland Haubner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Forschungsschwerpunkt Innovative Krebsdiagnostik und -therapie (E), Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Wolfhard Semmler (Leiter der Abteilung für Medizinische Physik in der Radiologie (E 020) (Leiter der Abteilung für Medizinische Physik in der Radiologie (E 020)

  2. Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts des Isar des Technischen Universität München, Ismaninger Str. 22, 81675, München, Germany

    Markus Schwaiger

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Haubner, R. (2008). Noninvasive Tracer Techniques to Characterize Angiogenesis. In: Semmler, W., Schwaiger, M. (eds) Molecular Imaging II. Handbook of Experimental Pharmacology, vol 185/2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77496-9_14

Download citation

Publish with us

Policies and ethics

Search

Navigation